JPRN-jRCT2031220368进行中（未招募）2 期
ROH-201 ophthalmic solution phase IIb clinical trial
Mantani Tomomi0 个研究点目标入组 300 人开始时间: 2022年10月7日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Tear film break-up time of <= 5 seconds
- •- Have a subjective symptoms of Dry Eye Disease
- •- 20 years and older at the time of Informed Consent
排除标准
- •- Contact lens wearers who cannot discontinue the wear over the trial period
研究者
相似试验
已完成
2 期
ROH-201 ophthalmic solution Phase 2a clinical trialDry eye diseaseJPRN-jRCT2051200158Kitano Takashi80
招募中
1 期
ROH-001 ophthalmic solution phase I clinical trial -Single and multiple dose studyHealthy volunteerJPRN-jRCT2051230128Mantani Tomomi48
已完成
3 期
Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired BlepharoptosisAcquired BlepharoptosisNCT02436759RVL Pharmaceuticals, Inc.140
进行中（未招募）
1 期
A Phase II, pilot clinical trial to evaluate the effects of atorvastatin on Graves' Orbitopathy (GO) in hypercholesterolemic patients with moderate-to-severe and active GO subjected to intravenous glucocorticoid therapy.Graves’ orbitopathy is a disabling and disfiguring disease affecting the eyes observed in approximately 25-30% of patients with Graves’ disease. Its clinical manifestations include exophthalmos, inflammatory signs and symptoms, diplopia, and in most severe cases sight impairment.MedDRA version: 20.0Level: PTClassification code 10004161Term: Basedow's diseaseSystem Organ Class: 10014698 - Endocrine disordersEUCTR2018-001317-33-ITAZIENDA OSPEDALIERO-UNIVERSITARIA PISANA88
已完成
2 期
Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With PresbyopiaPresbyopiaNCT05665387Santen Inc.79